LEE'S PHARM: Voluntary Announcement - The First Patient in Hong Kong Receives AU409, a Novel Drug Product Manufactured by Zhaoke Guangzhou, in a Phase I Liver Cancer Clinical Trial
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
LEE'S PHARM: List of Directors and their Roles and Functions
LEE'S PHARM: Appointment of Non-Executive Director
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
LEE'S PHARM: Notification Letter to Non-registered Shareholders and Reply Form
LEE'S PHARM: Notification Letter to Registered Shareholders and Reply Form
LEE'S PHARM: Proxy Form
LEE'S PHARM: Environmental, Social and Governance Report 2023
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
LEE'S PHARM: Final Dividend for the Year Ended 31 December 2023
LEE'S PHARM: Letter to Non-registered Shareholders - Arrangement for Electronic Dissemination of Corporate Communications and Reply Form
LEE'S PHARM: Letter to Registered Shareholders - Arrangement for Electronic Dissemination of Corporate Communications and Reply Form
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
LEE'S PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
LEE'S PHARM: Voluntary Announcement - Adasuve Obtains Drug Registration Certificate
No Data